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7SUMMARY
Reactive oxygen species (ROS) have been implicated in many pathological
situations, from complications of oxygen therapy in preterm infants to diseases in
adult medicine, including hypertension. Glutathione (GSH) is one of the most
important endogenous antioxidants in the cell. Its synthesis is dependent on the
activity of the rate-limiting enzyme, g-glutamylcysteine synthetase (GCS), and
the availability of the substrate, cysteine, which is either derived from the diet or
protein catabolism, or synthesized from methionine in the liver by the
transsulfuration pathway.
The present study was designed to investigate the ability of the premature
neonate to synthesize glutathione, and to generate cysteine through the
transsulfuration pathway. To this end, the expression of GCS in human tissues
relevant to neonatal oxidative injury as well as the hepatic expression of two
forms of cystathionine g-lyase (CGL), the last enzyme of the transsulfuration
pathway, were studied during development. Moreover, the ability of the two
mRNA isoforms to code for active enzyme was assessed. The role of glutathione
in hypertension was studied in a genetic animal model of hypertension, the
spontaneously hypertensive rat (SHR).
The mRNA expression and enzyme activity of GCS were studied in lung, liver
and kidney tissue, and CGL in liver tissue derived from abortions, neonatal
autopsies or transplantations. The ability of the two CGL mRNA forms to code
for active enzyme was investigated by transfecting the corresponding cDNAs into
eukaryotic cells. The activity of GCS and three other enzymes involved in GSH
metabolism, glutathione peroxidase (GPx), glutathione reductase (GR) and
glucose-6-phosphate dehydrogenase (G6PDH) were measured in the kidney,
myocardium and liver of SHR and its normotensive control strain, Wistar-Kyoto
(WKY).
GCS was expressed and active in all tissues studied from early 2nd trimester.
Strong mRNA expression of both CGL isoforms was detected from the 19th
gestational week onwards, while enzyme activity was detected only in adult liver.
Only the longer CGL isoform was enzymatically active in transfected cells. In the
kidney of SHR, nitric oxide synthase (NOS) inhibition caused a decrease in GCS
activity, which was further augmented by a high sodium intake.
In conclusion, GCS appears to be fully functional from early stages of
development in tissues studied implying that GCS does not limit GSH synthesis
in preterm neonates. However, as CGL activity is absent from fetal and neonatal
liver, insufficient synthesis of cysteine may account for low GSH levels in
premature infants. In an experimental animal model of hypertension, NOS
inhibition down-regulates GSH synthesis, which may aggravate hypertensive
kidney injury.
8INTRODUCTION
Reactive oxygen and nitrogen species (ROS and RNS, respectively)  are
implicated in many pathological situations. These range from clinical
complications of premature infants related to oxygen therapy, such as chronic
lung disease, to problems in adult medicine, such as cardiovascular diseases.
While ROS and RNS are produced even in normal cellular metabolism, their
production in pathophysiological situations exceeds the capacity of the cell to
provide defense against their damaging effects. Thus the balance between ROS
production and the antioxidant defense is critical in determining the extent of the
damage caused by these highly reactive molecules.
Glutathione (g-glutamylcysteinylglycine, GSH) is one of the most important
antioxidants present in the cell. It has a number of other functions, such as
detoxification of xenobiotics, regulation of the redox-state of sulfhydryl groups
of proteins, as well as participation in DNA, protein, and leukotriene synthesis.
Cells synthesize GSH by two ATP-dependent enzymes, g-glutamylcysteine
synthetase (GCS), and glutathione synthetase. GCS is the rate-limiting enzyme
and it is feed-back inhibited by GSH. GCS is also regulated by ROS and RNS.
The rate of GSH synthesis may also be limited by the availability of one of its
three precursor amino acids, cysteine, which is either provided in the diet or
synthesized in the liver from methionine in a metabolic pathway called
transsulfuration.
This series of studies were undertaken to elucidate the role of the enzymes
involved in glutathione synthesis during human development and in experimental
hypertension.
9REVIEW OF THE LITERATURE
Reactive oxygen and nitrogen species
Reactive oxygen and nitrogen species (ROS and RNS, respectively) include a
number of highly reactive molecules (Table 1). Some of these species are defined
as free radicals, any atom or molecule having an unpaired electron in its outer
orbit (Halliwell and Gutteridge 1989). Others, however, are not radicals but
nevertheless are active metabolites of oxygen and nitrogen. Examples of such
molecules are hydrogen peroxide (H2O2), which reacts with divalent cations in
the Fenton reaction, thereby forming the very reactive hydroxyl radical (OH·)
(Halliwell and Gutteridge 1989), and peroxynitrite (ONOO- ), formed by the
reaction of superoxide (O2·- ) and nitric oxide (NO· ).
Production
ROS are generated in the normal aerobic metabolism of cells in a variety of
reactions (Table 2). The main source of ROS is mitochondria, where oxygen is
reduced to water in the electron transport chain (Halliwell and Gutteridge 1989).
About 1% of the oxygen reduced by mitochondria is converted to O2·-
 (Turrens
1997), at the level of NADH dehydrogenase (Turrens and Boveris 1980) or
coenzyme Q (Cadenas et al. 1977). Mitochondrial O2·-
 can be further dismutated
to H2O2 (Fridovich and Freeman 1986). With regard to hyperoxic lung injury in
neonates, it is of interest to note that mitochondrial production of ROS is
increased in hyperoxia (Freeman and Crapo 1981).
Table 1. Reactive oxygen and nitrogen species
Reactive oxygen species (ROS) Reactive nitrogen species (RNS)
O2·- superoxide NO· nitric oxide
OH· hydroxyl NO2 nitrogen dioxide
LOO· lipid peroxyl N2O3 dinitrogen trioxide
LO· lipid alkoxyl ONOO- peroxynitrite
H2O2 hydrogen peroxide ONOOH peroxynitrous acid
HOCl hypochlorous acid
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Table 2. Cellular sources of ROS
Source Localization
Electron transport system Mitochondria
NADPH oxidase Plasma membrane
Cyclo-oxygenases
Lipoxygenases
Xanthine oxidase Cytosol
Catecholamines
Riboflavin
Transition metals (Fe2+/3+, Cu1+/2+)
Oxidases Peroxisome
Nuclear membrane electron transport Endoplasmic reticulum
(cytochromes P-450, and b5)
Besides mitochondria, important cellular sites of ROS generation relevant to
the present study are membrane-bound NAD(P)H oxidases. NAD(P)H oxidases
generate large amounts of O2·-
 in activated inflammatory cells (Rossi 1986), but
in vascular cells the enzyme responsible for NADPH oxidase-like activity
appears to be different and produces O2·-
 in much smaller quantities (Mohazzab
et al. 1994). While the role of different ROS-generating systems in the
vasculature is far from clear, evidence suggests that NADPH oxidase-like activity
is a contributing source of ROS in endothelial cells (Mohazzab et al. 1994),
vascular smooth muscle cells (Griendling et al. 1994), and intact aortas
(Rajagopalan et al. 1996) in response to a variety of stimuli such as angiotensin II
and cytokines. This may have implications in hypertension, as angiotensin II is a
potent vasoconstrictor and some forms of hypertension are associated with
elevated levels of this peptide.
Nitric oxide is synthesized from L-arginine in a reaction catalyzed by the
enzyme nitric oxide synthase (NOS), which utilizes molecular oxygen and
NADPH as co-substrates (Griffith and Stuehr 1995). There are three isoforms of
this enzyme, type I (neuronal nitric oxide synthase, nNOS), type II (inducible
nitric oxide synthase, iNOS), and type III (endothelial nitric oxide synthase,
eNOS). Type I and III are referred to as the constitutive form (cNOS). These
isoforms are continuously present in the cell and they can be activated by Ca2+.
NOS I and NOS III generate low fluxes of NO· , whereas the Ca2+ independent
iNOS, originally discovered in cytokine-induced macrophages, is a high-output
enzyme induced by cytokines, LPS and other bacterial products. Although termed
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as constitutive, NOS I and III are also subject to regulation. Expression is
enhanced by, for example, estrogens (NOS I and III), shear stress, TGF-b1, and
high glucose (NOS III) (Forstermann et al. 1998). Interestingly, under certain
circumstances NOS I (Pou et al. 1992) and NOS III (Vasquez-Vivar et al. 1998)
can generate O2·- , which may have important implications in vascular diseases
characterized by endothelial dysfunction, such  as hypertension.
Cellular effects of ROS and RNS
ROS and RNS may cause peroxidation of lipids, denaturation of proteins and
damage to nuclear acids (Figure 1). Thus almost all cellular components can be
injured by them (Freeman and Crapo 1982). In cellular membranes, ROS cause
peroxidation of polyunsaturated fatty acids. This reaction is initiated by
abstraction of a hydrogen atom from the lipid molecule and is followed by
autocatalytic propagation, in which lipid hydroperoxides and lipid radicals are
formed. This cascade can be terminated by the reaction of two peroxyl radicals or
the reaction of a peroxyl radical with an antioxidant molecule. NO·  can also
terminate a lipid peroxidation process by reacting with a peroxyl radical (Wink
and Mitchell 1998). However, in the presence of superoxide, nitric oxide forms
peroxynitrite, a powerful oxidant capable of initiating lipid peroxidation (Radi et
al. 1991, Hogg and Kalyanaraman 1999).
Figure 1. Sources  of reactive oxygen species and antioxidant pathways
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Proteins can undergo numerous covalent changes upon exposure to oxidants
(Dean et al. 1997). For example, radical-mediated oxidation induces the
formation of amino acyl carbonyl groups (Stadtman 1990). The sulfhydryl moiety
of cysteine is highly prone to oxidative attack leading to formation of disulfide
bonds. Peroxynitrate causes oxidative modification of a number of amino acid
residues (Ischiropoulos and al-Mehdi 1995). These reactions lead to protein
inactivation and, ultimately, to proteolytic degradation. However, some
modifications, such as thiol-disulfide exchange or tyrosine nitration, are fairly
specific and these are postulated to be regulatory (Gilbert 1984, Ischiropoulos
1998).
In DNA, ROS and RNS can cause structural alterations in DNA such as base
pair mutations, rearrangements, deletions, insertions and sequence amplification
(Wiseman and Halliwell 1996). OH·  is especially damaging, modifying purine
and pyrimidine bases of DNA as well as the sugar backbones of DNA.
ROS and RNS are not only deleterious, but they can serve as signaling
molecules during normal cellular metabolism (Finkel 1998). ROS have been
shown to affect multiple cell signaling pathways such as protein kinase C, signal
transducer and activator of transcription (STAT) factors and mitogen activated
protein (MAP) kinases, which link extracellular stimuli to cellular responses such
as cell proliferation, differentiation, and cell death (Suzuki et al. 1997, Griendling
and Harrison 1999). Several transcription factors, including AP-1, AP-2 and NF-
kB, are redox-regulated (Dalton et al. 1999). Moreover, the activity of metabolic
enzymes may be regulated by the oxidation state of critical thiol groups (Gilbert
1984). NO·  exhibits a number of regulatory properties ranging from the
regulation of the mitochondrial respiration through inhibition of cytochrome c
oxidase (Torres et al. 1995), to the cGMP-dependent vasorelaxation, the first
NO· -dependent signaling event discovered (Ignarro et al. 1987). Thus ROS and
RNS work as signaling molecules in multiple cellular sites and metabolic events,
and the physiological role of oxidants in cell regulation and their mechanisms of
action are only emerging.
13
Defense against ROS and RNS
Antioxidant enzymes
Superoxide dismutases (SODs), first described by McCord and Fridovich (1969),
are metalloproteins that dispose effectively and specifically of superoxide anions
(Figure 1). These enzymes facilitate the dismutation of two otherwise repulsive
O2·-
 radicals, which join to form hydrogen peroxide (Fridovich 1978). In
eukaryotes, three different forms of SODs have been characterized: a copper and
zinc containing form (CuZn-SOD) that is localized in the cytosol, a manganese
containing form (MnSOD) in the mitochondria (Slot et al. 1986) and a copper-
and zinc-containing extracellular form (ECSOD) in the extracellular matrix
(Marklund 1984).
Catalase, localized mainly in peroxisomes in the cell, enhance the reaction by
which two hydrogen peroxide molecules decompose to water and oxygen (Figure
1) (Fridovich 1978). The enzyme does not metabolize alkyl hydroperoxides
(Chance et al. 1979). Its high Km value for H2O2 and compartmentalization to
peroxisomes implies that its role is mainly to protect the cell against H2O2
produced in these organelles. The role in H2O2 catabolism at low rates of H2O2
production is probably of minor importance (Jones et al. 1981).
The glutathione redox cycle is a central mechanism in scavenging alkyl
hydroperoxides, but it is also active in metabolizing H2O2 (Chance et al. 1979).
The enzymes in the cycle include glutathione peroxidase (GPx) and glutathione
reductase (GR). Because GPx has a lower Km value for H2O2 than catalase, it is
considered more important when low levels of H2O2 are produced.
 Recently, a peroxiredoxin (Prx) family of proteins has been shown to possess
peroxidase-like activity (Kang et al. 1998). These enzymes do not use glutathione
as a cofactor but rely on thioredoxin as a source of reducing equivalents for the
reduction of H2O2. The biological importance of Prx in H2O2 disposal remains to
be elucidated.
Scavengers and antioxidant molecules
There are a number of molecules capable of inhibiting oxidation reactions due to
ROS either by preventing their formation or by scavenging them, thus inhibiting
the chain-reaction. Metal chelating agents, such as desferrioxamine, or proteins,
such as transferrin, ferritin, metallothionein and ceruloplasmin, sequester metal
ions and thus prevent the formation of noxious oxidants by the Fenton reaction
(Halliwell and Gutteridge 1989). Many antioxidants are low molecular weight
compounds that are either synthesized by the cells or derived from the diet. An
important lipid-soluble antioxidant is -tocopherol (vitamin E), which acts in
cellular membranes as a chain-breaking antioxidant of lipid peroxidation by
donating hydrogen to peroxyl radicals. -tocopherol works in concert with water-
soluble ascorbate (vitamin C), which re-reduces the tocopheroxyl radical
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(Buettner 1993). Ascorbate also scavenges effectively superoxide, singlet oxygen
and hydroxyl radicals. In addition, it can spare intracellular GSH (Meister 1994).
Other endogenous small molecular weight antioxidants include uric acid, which
is synthesized by xanthine dehydrogenase and bilirubin, produced by heme
oxygenase (Halliwell and Gutteridge 1989).
Glutathione
Glutathione (L-g-glutamyl-L-cysteinylglycine) (Figure 2) is a tripeptide present in
virtually all animal cells (Meister and Anderson 1983). It is usually the most
abundant intracellular small molecular weight thiol, present in the millimolar
range in mammalian cells. The peptidic g-linkage between glutamic acid and
cysteine is thought to protect the tripitide from degradation by aminopeptidases.
Glutathione is also less prone to oxidation than cysteine, making it an ideal
compound for maintaining intracellular redox potential. Glutathione exists either
in reduced (thiol, GSH) or oxidized (disulfide, GSSG) form (Figure 2). GSH is
the predominant form, and GSSG content is usually less than 1% of GSH. In the
cell, almost 90% of glutathione is in the cytosol, 10% in the mitochondria and a
small percentage in the endoplasmic reticulum and in the nucleus (Meister 1991).
Mitochondria appear to have a distinct pool of GSH that is resistant to GSH
depletion (Meister 1991). Mitochondria do not synthesize GSH themselves but
import it through an as yet unidentified ATP-dependent mechanism (Fernandez-
Checa et al. 1998). As mitochondria do not contain catalase, GSH-dependent
reactions are thought to be the main mechanism by which mitochondria dispose
of hydrogen peroxide (Meister 1991), though the recent characterization of the
thioredoxin-redox system implies that these could be involved as well (Pedrajas
et al. 1999). Hydrogen peroxide can also diffuse to the cytosol and be
metabolized there.
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Figure 2. Glutathione and glutathione disulfide
Antioxidant function of GSH
Disposal of hydrogen peroxide and lipid peroxides is catalyzed by isoforms of
GSH peroxidase (GPx). As a consequence, GSH is oxidized to GSSG, which is
then reduced back to GSH by GSSG reductase at the expense of NADPH,
thereby forming a redox cycle (Figure 3). The main pathway for NADPH
regeneration is the pentose phosphate shunt. In addition to GPx, GSH-S-
transferases may dispose of lipid peroxides in the cell (Awasthi et al. 1980). In
addition to enzymatic disposal of peroxides, GSH can also react non-
enzymatically with OH· , N2O3 and ONOO-  (Wink and Mitchell 1998).
The family of glutathione peroxidases is comprised of four distinct
selenoproteins. The classical or cytosolic glutathione peroxidase (cGPx) was the
first mammalian selenoprotein to be characterized (Flohe et al. 1973) (Rotruck et
al. 1973). Later on, phospholipid hydrolipid glutathione peroxidase (PHGPx)
(Ursini et al. 1982, Brigelius-Flohe et al. 1994), plasma GPx (pGPx) (Takahashi
et al. 1987), a gastrointestinal form of GPx (GI-GPx) (Chu et al. 1993), and non-
selenium dependent GPx (Shichi and Demar 1990, Fisher et al. 1999) were
identified. All glutathione peroxidases reduce hydrogen peroxide and alkyl
hydroperoxides, but their specificities for the hydroperoxide differ. They use
GSH as thiol substrate, but other substrates, such as thioredoxin (Bjornstedt et al.
1994) may also be used. The abundance of different GPx isoforms may reflect
the different roles of hydroperoxides in signaling in various tissues, cells and
cellular compartments (Brigelius-Flohe 1999).
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Figure 3. Glutathione redox cycle.
Two strains of cGPx knockout mice have been created independently (Ho et
al. 1997, de Haan et al. 1998). The mice grew and developed normally and did
not show any histopathologies, indicating a limited role of cGPx during normal
development and under physiologic conditions. Furthermore, these mice did not
show increased susceptibility to hyperbaric oxygen (Ho et al. 1997). However,
when stressed with paraquat, cGPx (-/-) mice died faster than controls (de Haan
et al. 1998). The  mice were also susceptible to ischaemia-reperfusion injury
(Yoshida et al. 1997). These studies imply that cGPx is important in the
protection against oxidative stress.
Recently, GSH has been shown to play a major role in the protection against
cytotoxic effects of ONOO-  (Ma et al. 1997). The protective mechanism is yet to
be elucidated. The direct interaction of ONOO-  with the thiol group of GSH is
rapid enough, in view of the high intracellular concentration, to make it
significant (Koppenol et al. 1992). It has also been proposed that GPx (Sies et al.
1997) and other selenoperoxidases (Arteel et al. 1998) can act as peroxynitrite
reductases, thereby preventing cellular damage caused by peroxynitrite.
Detoxifying functions of GSH
Detoxification of xenobiotics is one of the major functions of GSH. Toxic
electrophiles conjugate with GSH either spontaneously or enzymatically in
reactions catalyzed by GSH S-transferases (Whalen and Boyer 1998). GSH S-
transferases are a family of enzymes expressed in all human tissues, though the
expression of different isoenzymes is variable (Awasthi et al. 1994, Mainwaring
et al. 1996). In the liver, GSH-S transferases account for as much as 5-10% of the
total soluble protein (Whalen and Boyer 1998). Thus, the major pathway for
GSH utilization in the liver is through transferase reactions. The conjugation of
electrophiles with GSH is irreversible, and the resulting conjugates are excreted
from the cell. GSH conjugates can then be used for resynthesis of GSH through
the mercapturic pathway. In addition to exogenous substances, many
endogenously formed compounds, such as prostaglandins and leukotrienes,
conjugate with GSH by a similar mechanism (Wang and Ballatori 1998).
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Maintenance of intracellular thiol status by GSH
Accumulating evidence suggests that the GSH-GSSG redox couple is important
in regulating cellular proteins through reversible disulfide bond formation
(Dalton et al. 1999). The formation of inter- and intramolecular disulfides as well
as mixed disulfides between protein SH-groups and GSH, that is, protein
glutathiolation, has been implicated in regulation of enzyme activity and
transcription. Protein cysteinyl thiols react with GSSG. As the GSH/GSSG ratio
usually exceeds 100, small increases in GSSG concentration will promote
oxidation of protein cysteinyl thiols, shifting the equilibrium of thiol-disulfide
exchange significantly in the direction of mixed disulfide formation and the
formation of intra- and intermolecular disulfide bonds. Reduction of mixed
disulfides is enzyme-mediated by catalysts such as thioredoxin, glutaredoxin and
protein-disulfide isomerase (Cotgreave and Gerdes 1998). Many signal
transduction pathways and transcription factors fundamental for cell growth,
differentiation and apoptosis, appear to be redox-regulated. It has also been
postulated that the thiol-disulfide equilibrium within the cell may regulate certain
metabolic pathways by activating and inactivating enzymes (Gilbert 1982).
Protein thiol groups may also be modulated by S-nitrosothiols such as S-
nitrosoglutathione (GSNO) (Stamler and Hausladen 1998). S-nitrosothiols are
formed by the reaction of NO· -derived species with thiols, and it has been
suggested that these play a role in the storage and transport of NO·  (Gira d and
Potier 1993). GSNO is able to modify protein thiol groups by both protein S-
nitrosation and S-thiolation, and these modifications in critical thiols have been
postulated to be mechanisms by which NO·  controls cellular processes (Ji et al.
1999).
GSH in cysteine storage
One of the important functions of GSH is to store cysteine because it is less
prone to oxidation than cysteine (Meister 1991). The g-glutamyl cycle (Figure 4)
allows GSH to serve as a source of cysteine (Meister and Anderson 1983). GSH
is exported by a carrier-mediated transporter and transmembrane protein g-
glutamyl transpeptidase (g-GT) transfers the g-glutamyl moiety of GSH to an
amino acid, preferably cystine thereby forming g-glutamyl amino acid and
cysteinylglycine. g-glutamyl amino acid can then be transported back into the
cell. Inside the cell, the  g-glutamyl amino acid can be further metabolized by g-
glutamylcyclotransferase to release amino acid and 5-oxoproline, which then can
be converted by 5-oxoprolinase to glutamate and used for resynthesis of GSH.
Extracellular cysteinylglycine may be either split extracellularly by dipeptidase to
form cysteine and glycine, or it can be transported into the cell as such,
hydrolyzed and used for resynthesis of GSH.
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The liver has been identified as the central organ in the interorgan homeostasis
of GSH. The liver is not only able to synthesize GSH from its constituent amino
acids glutamine, cysteine and glycine, but it also has an unique capacity to
synthesize cysteine from methionine through the transsulfuration pathway (Reed
and Orrenius 1977, Beatty and Reed 1980). Furthermore, liver epithelial cells
have a high capacity for GSH efflux (Ookhtens and Kaplowitz 1998), with
sinusoidal GSH export as the major determinant of plasma levels of low
molecular weight thiols. GSH is excreted from a sinusoidal cell by carrier-
mediated transporters that are yet to be characterized in detail (Ookhtens and
Kaplowitz 1998). Certain stress hormones, such as adrenaline and phenylephrine,
have been shown to enhance sinusoidal efflux of GSH, making more hepatic
GSH available to systemic circulation (Sies and Graf 1985). In human, the
exported GSH is mainly degraded to its constituent amino acids by g-GT and
dipeptidase in the liver (Hinchman and Ballatori 1990), and the main small
molecular weight thiol in plasma is cysteine (or its oxidized form cystine)
(Speisky et al. 1990). Plasma cysteine can then be used for GSH resynthesis in
extrahepatic tissues. Alternatively, GSH can be used through the g-glutamyl cycle
in extra-hepatic tissues rich in g-GT, such as kidney (Griffith and Meister 1979),
and lung (Martensson et al. 1989).
The lung epithelium has been shown to have high levels of g-GT activity and it
utilizes extracellular GSH from alveolar lining fluid (Berggren et al. 1984). g-GT
expression is increased in rat lung epithelial cells by oxidants such as menadione
and t-butylhydroquinone (Kugelman et al. 1994), suggesting that g-GT may play
a role in the protection against oxidative stress in the lung. However, oxidative
stress has no effect on g-GT activity in human type II alveolar epithelial cells
(A549 cells) (Rahman et al. 1998). Furthermore, only rare columnar epithelial
cells in bronchi and terminal bronchioles are g-GT immunopositive in mouse lung
(Lieberman et al. 1995). Therefore, the involvement of g-GT i  the regulation of
lung GSH levels during oxidative stress in vivo remains unproven.
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Figure 4. g-glutamyl cycle. Abbreviations: DP, dipeptidase; Cys, cysteine; GCS,
g-glutamylcysteine synthetase; GS, glutathione synthetase; g-Glu-cy , g-
glutamylcysteine; g-GT, g-glutamyl transpeptidase; Glu, L-glutamic acid; Gly,
glycine, GSH, glutathione.
Glutathione biosynthesis
GSH is synthesized from cysteine, glutamate and glycine by the consecutive
actions of two ATP-dependent enzymes, g-glutamylcysteine synthetase (GCS, EC
6.3.2.2) and glutathione synthetase (EC 6.3.2.3) (Meister 1995) (Figure 4). Both
enzymes are exclusively cytosolic. The first step in GSH biosynthesis catalyzed
by GCS is rate-limiting, while GSH synthetase apparently has no regulatory role
(Lu 1999). Physiologically, GCS is regulated either by competitive, non-
allosteric inhibition by GSH (Richman and Meister 1975) or by the availability of
GSH precursor, cysteine (Deneke and Fanburg 1989). While the intracellular
glutamate concentration is several-fold higher than the Km value of GCS for
glutamate,  the intracellular cysteine concentration approximates the Km value for
cysteine (0.1-0.3 mM) (Lu 1999).
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g-glutamylcysteine synthetase
The mammalian g-glutamylcysteine synthetase (GCS) is a heterodimer consisting
of a heavy (GCSh, 73 kDa) and a light (GCSl, 28 kDa) subunit, and these can be
dissociated under non-denaturing conditions by dithiothreitol (Seelig et al. 1984).
All the catalytic activity of the enzyme, as well as the site for feed-back
inhibition by GSH, resides in GCSh, while GCSl serves a regulatory function
(Huang et al. 1993a, Huang et al. 1993b). When the light subunit is present, the
Km for L-glutamate of rat kidney holoenzyme is reduced from 18 mM to 1.4 mM
and the Ki for GSH is increased from 1.8 mM to 8.2 mM. The kinetics of the
recombinant human enzyme are similar (Misra and Griffith 1998). Since
intracellular levels of L-glutamate and GSH are 1-3 mM and 1-10 mM,
respectively, it is likely that the presence of the light subunit is needed for full
activity of GCS in vivo (Huang et al. 1993a, Huang et al. 1993b).
GSH synthesis is enhanced through upregulation of GCS in a variety of cells
and organs after exposure to agents that cause oxidative stress (Table 3, see (Lu
1999) and (Rahman and MacNee 1999)). These agents increase GCSh mRNA
levels mostly through increased transcription, but in some cases through mRNA
stabilization as well. Oxidative agents increase also the transcription of GCSl.
Thus, upon oxidative stress there appears to be a concomitant induction of both
subunits, enhancing GSH synthesis and thereby increasing cellular tolerance
against oxidative stress.
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Table 3. Agents that induce g-glutamylcysteine synthetase and elevate
glutathione (modified from Lu,  (Lu 1999), and Rahman and MacNee (Rahman
and MacNee 1999)).
Agent Cell/organ
Oxidants
H2O2 Human alveolar type II cells (A549)
Dimethylnaphthoquinone Rat lung cells (L2)
t-Butylhydroquinone Human hepatocyte cells (HepG2)
Hyperoxia A549 cells, rat lung
Pyrrolidine dithiocarbamate HepG2 and bovine aortic endothelial cells
b-naphthoflavone HepG2 cells
Cytokines
TNF-a HepG2, A549 cells
IL-1b endothelial cells
Heavy metals
Cadmium A549 cells
Mercury Rat kidney
NO donors
S-nitroso-N-penicillamine Bovine aortic endothelial and rat vascular
smooth muscle cells
DETA NONOate Bovine aortic endothelial and r t vascular
smooth muscle cells
Nitric oxide increases intracellular GSH by inducing GCS in rat vascular
smooth muscle cells (Moellering et al. 1998) and bovine endothelial cells
(Moellering et al. 1999a). NO donors also increase GSH concentration in rat lung
fibroblasts, possibly through a similar mechanism (White et al. 1995). In vascular
smooth muscle cells, NO·  fluxes at or above 8 nM/s increase the mRNA
expression of both subunits (Moellering et al. 1998). In endothelial cells, lower
rates of production, 1-3 nM/s, corresponding to the rate required for NOS III to
elicit vasodilation (Kanai et al. 1995), are sufficient to induce GCS (Moellering
et al. 1999a). The induction of GCS by NO·  appears to be a cGMP independent
event (Moellering et al. 1998, Moellering et al. 1999a).
The 5’-flanking regions of both GCS subunits have been cloned and sequenced
(Figure 5) (Mulcahy et al. 1997, Moinova and Mulcahy 1998). Putative activator
protein-1 (AP-1), nuclear factor kappa B (NF-k ), activator protein-2 (AP-2),
and several antioxidant responsive elements (ARE; also referred to as electrophil
responsible element or EpRE), have been identified in the promoter region of the
GCSh gene (Mulcahy and Gipp 1995, Mulcahy et al. 1997). The basal
transcription of the gene is driven by sequences between -202 and +22,
containing a consensus TATA box (Mulcahy et al. 1997). AP-1 or AP-1-like
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responsive elements residing in the region of -817 to +82 of the promoter
sequence have been shown to be important for transcriptional induction by
various agents that increase ROS production, such as TNF-a (Morales et al.
1997, Rahman et al. 1999), menadione (Rahman et al. 1996) and H2O2 (Rahman
et al. 1996), while NF-kB appears to have no effect on induction by menadione
or H2O2 (Rahman 1998), or by TNF-a (Morales et al. 1997, Rahman et al. 1999).
Distal ARE/EpRE (ARE 4, Figure 5) sequences have been shown to be important
in the induction of GCSh by electrophilic compounds b-naphthoflavone (Mulcahy
et al. 1997) and pyrrolidine dithiocarbamate (PDTC) (Wild and Mulcahy 1999)
through post-translational activation of transcription factor Nrf2 (Wild et al.
1999, Itoh et al. 1999). In addition, the metal responsive element (MRE), which
is also involved in the regulation of general cellular stress response, appears to be
crucial for GCSh gene expression in response to heavy metals as well as for the
constitutive expression of the gene in the liver (Gunes et al. 1998).
The basal expression of the GCSl gene is directed by a consensus AP-1 site at
-340:-334 of the promoter sequence (Moinova and Mulcahy 1998). It is also
involved in b-naphthoflavone-mediated induction together with the EpRE site at -
301:-291 (Moinova and Mulcahy 1998). As in GCSh, Nrf2 appears to mediate the
induction through EpRE, possibly through complex formation with Maf proteins
and JunD (Wild et al. 1999).
Figure 5. Promoter regions of GCSh and GCSl genes.
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The availability of cysteine as a determinant of GSH synthesis
The hepatic GSH level appears to be largely dependent on dietary cysteine and
methionine, derived from dietary protein. In rat liver, starvation for 48 hours
reduces liver GSH to between two thirds and one half of the normal levels. The
GSH levels are quickly replenished upon refeeding (Tateishi et al. 1974). Liver
GCS activity and mRNA expression are down-regulated in a dose-dependent
manner by high sulfur amino acid or protein content in the diet (Bella et al. 1996,
Bella et al. 1999a, Bella et al. 1999b). Thus, substrate availability rather than
GCS activity appear to regulate GSH synthesis in the liver.
Cysteine is transported into the cell by sodium-dependent A or ASC systems
(Bannai 1984). Intracellular cysteine concentrations can be increased also by
cystine, which is reduced intracellularly to yield cysteine. The transport of
cystine is distinct from that of cysteine, and it utilizes the Xc- transport system
(Bannai 1986). This system is sodium-independent and mediates one-to-one
exchange to glutamate. Xc- transport system has been shown to be induced by
various oxidants and hyperoxia (Deneke et al. 1989, Miura et al. 1992), as well
as by NO·  (Li et al. 1999) leading to increased GSH synthesis and intracellular
GSH levels.
Transsulfuration pathway
The liver is the main site for cysteine biosynthesis, which occurs through the
transsulfuration pathway. In transsulfuration, methionine is sequentially
converted into cysteine via several enzymatic steps (Figure 6.). The first step is
the ATP-dependent activation of methionine to S-adenosylmethionine (SAM),
and it is catalyzed by methionine adenosyltransferase. Subsequent demethylation
and removal of the adenosyl moiety yields homocysteine. Homocysteine
condenses with serine to form cystathionine in a reaction catalyzed by
cystathionine synthase. Cleavage of cystathionine, catalyzed by cystathionine g-
lyase, releases free cysteine. In this pathway, methionine and homocysteine are
readily interconvertible, but the subsequent step, the formation of cystathionine,
is irreversible.
Availability of methionine appears to be the principal determinant regulating
the activity of transsulfuration and remethylation pathways. The main regulatory
control appears to be exerted at the level of homocysteine: when methionine is
needed, homocysteine is remethylated by methionine synthase or betaine-
homocysteine methyltransferase; when methionine is in excess, metabolism of
homocysteine via the cystathionine synthase reaction is accelerated (Selhub
1999). Interestingly, cystathionine b-synthase is a heme protein that under
reducing conditions exhibits a 1.7-fold lower activity than under oxidizing
conditions (Taoka et al. 1998). It has been postulated that under oxidative stress,
homocysteine transsulfuration is favored over remethylation, thereby increasing
the supply of cysteine for GSH synthesis. However, liver methionine
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adenosyltransferase is known to be inactivated upon oxidative and nitrosative
stress (Corrales et al. 1991, Avila et al. 1997, Sanchez-Gongora et al. 1997),
which leads to a decreased production of S-adenosylmethionine and subsequent
decrease in liver GSH levels (Lu 1998).
The last enzyme of the transsulfuration pathway is cystathionine g-ly se (CGL,
g-cystathionase, EC 4.4.1.1). It catalyzes the conversion of L-cystathionine into
L-cysteine, a-ketobutyrate and ammonia.  Mammalian CGL is a pyridoxal 5’
phosphate (PLP) dependent enzyme consisting of four subunits each binding one
molecule of PLP (Matsuo Y 1958, Steegborn et al. 1999). Although the three-
dimensional structure of human CGL has not been elucidated, sequence
similarity suggests that the overall fold of the enzyme would resemble that of the
other members of the g-family of PLP-dependent enzymes cystathionine b-lyase
and cystathionine g-synthase (Alexander et al. 1994, Clausen et al. 1996, Clausen
et al. 1998, Steegborn et al. 1999). Two monomers are in close contact sharing
active site residues forming an active dimer. Two of these dimers then interact to
form a CGL tetramer.
Figure 6. Transsulfuration pathway. Numbers and abbreviations: 1) Methionine
adenosyltransferase, 2) Various methyltransferases, 3) S-adenosylhomocysteine
hydrolase, 4) cystathionine b-synthase, 5) methionine synthase, 6) betaine-
homocysteine methyltransferase, CGL, Cystathionine g-lyase.
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Both human (Lu et al. 1992) and rat (Erickson et al. 1990) cDNA for CGL
have been cloned. Two forms of human mRNA for CGL have been
characterized, of which the shorter form has an internal deletion of 132 base
pairs. As the human CGL gene has not been localized, it is not known whether
these two forms are products of different genes or splice variants. Furthermore, it
is not known whether both mRNAs are translated. As it has been shown that
CGL activity is absent from human fetal liver (Sturman et al. 1970), it was
proposed that the subunit composition of the tetrameric CGL regulates the
activity, and that the postnatal increase in CGL activity is caused by a change in
relative expression of the two isoforms (Lu et al. 1992). The absence of CGL
activity in the liver of preterm neonates has been shown to be associated with
lowered cysteine levels and, subsequently, impaired GSH synthesis (Vina et al.
1995).
ROS and antioxidants  in pathophysiology
Neonatal problems
Preterm infants may be deficient in pulmonary surfactant and are at risk for the
respiratory distress syndrome (RDS) during the first days of life. Such infants
often require ventilator therapy with high inspired oxygen concentrations to
provide adequate oxygenation. Prolonged ventilator treatment is associated with
the development of chronic lung disease (CLD). The typical morphologic
changes include airway epithelial damage, bronchial smooth muscle cell
hyperplasia and obstruction, as well as alveolar destruction and interstitial
fibrosis. Predisposing factors include immaturity, high ventilator pressures, and
high inspired oxygen concentrations. The histologic findings in CLD are
markedly similar to pulmonary oxygen toxicity in experimental animals (Frank
1992, Abman and Groothius 1994). Preterm neonates at risk for development of
CLD have shown an enhanced inflammatory reaction in the lungs with an
associated increase in pulmonary microvascular permeability (Groneck et al.
1994). Inflammatory cells contribute to the lung injury by releasing proteolytic
enzymes and ROS, which damage pulmonary cells and alter their function
(Pierce and Bancalari 1995).
There is ample indirect evidence that ROS are associated with CLD. The
amount of lipid peroxidation products, pentane and ethane, in expired air of very
low birth weight infants is increased, and the amounts are significantly higher in
patients with a poor outcome (Pitkänen et al. 1990). The amount of protein
carbonyls, a marker for protein oxidation, in tracheal aspirates of those infants
developing CLD is markedly higher than those that do not (Varsila et al. 1995).
Infants that subsequently develop CLD have increased plasma levels of allantoin,
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a non-enzymatic oxidative product of uric acid (Ogihara et al. 1996), as well as
increased concentrations of lipid peroxidation products (Ogihara et al. 1999).
Also RNS may play a role in the pathogenesis of CLD, as plasma nitrotyrosine
levels are increased (Banks et al. 1998).
Apart from CLD, ROS have been ascribed a role in other common problems of
prematurity, such as retinopathy of prematurity (ROP), and necrotizing
enterocolitis (NEC) (Warner and Wispe 1992). The association of ROP, which is
a developmental vascular disorder of the retina, with prolonged oxygen therapy is
well established, leading to the hypothesis that increased free radical formation in
hyperoxia would cause aberrant vessel formation (Kretzer and Hittner 1988).
However, arterial oxygen levels in premature infants requiring oxygen therapy
are lower than in healthy neonates breathing room air, and experimental data
suggest that the fluctuation in arterial oxygen levels and degree of hypoxia may
have more influence on proliferative retinal disease than extended hyperoxia
(Penn et al. 1995). The pathogenesis of NEC is multifactorial, but ischemia and
subsequent reperfusion with increased ROS production are likely to contribute to
the injury (Warner and Wispe 1992).
Taken together, the association of ROS with neonatal lung injury is fairly well
established. In other neonatal clinical complications, more clinical and
experimental data are needed to confirm the involvement of ROS in
pathophysiological processes.
Antioxidant defense of the newborn
It has been demonstrated in a number of animal species that a several-fold
increase in the activities of fetal lung antioxidant enzymes, MnSOD and
CuZnSOD, catalase and GPx, normally occurs during the final 15-20% of
gestation (Frank 1991). This has been considered a defense mechanism against
air breathing and relative hyperoxia after birth. Insufficient activity of antioxidant
enzymes in the lung of the preterm neonate is thought to aggravate the damage
resulting from ventilatory care. However, coordinated induction of antioxidant
enzymes does not appear to take place in the human lung (Fryer et al. 1986,
Strange et al. 1988, Strange et al. 1990, McElroy et al. 1992, Asikainen et al.
1998). The expression of MnSOD, CuZnSOD, catalase and GPx in human
infants born prematurely is similar to that in adults, which indicates that preterm
neonates are better adapted for life in an oxygen-containing environment than
previously suspected.
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Little is known about the ontogeny of the enzymes important for glutathione
synthesis. The activities of GCS are significantly lower in the kidneys of neonatal
mice, but the liver and lung have levels similar to those of adults (Harman et al.
1990). A similar trend has also been reported in rats (Tsui and Yeung 1979).  In
human fetal erythrocytes (Lestas and Rodeck 1984), leukocytes (Lavoie and
Chessex 1998), and liver (Rollins et al. 1981), GCS activities are in the same
range as in adults.
Cystathionine g-lyase activity (Sturman et al. 1970), as well as
immunoreactive protein (Gaull et al. 1972), is absent from human fetal liver,
although other enzymes of the transsulfuration pathway are present. In rats,
activity in the liver is low during fetal development and increases rapidly during
the last 3 days of gestation (Heinonen 1973). The rate of GSH synthesis from
methionine is 6 times lower in fetal than in adult rat hepatocytes, presumably due
to the low CGL activity (Pallardo et al. 1991). In preterm infants, plasma cysteine
levels are much lower than in full term newborns (White et al. 1994, Vina et al.
1995),  reflecting low cystathionase activity. Studies on very low birth weight
infants during the first week of life, when they are mostly on parenteral nutrition,
have shown that plasma cysteine levels decrease more, relative to term reference
values, than those of any other amino acid (Van Goudoever et al. 1995). In
addition, concentration of GSH in plasma and bronchoalveolar lavage fluid is
inversely proportional to gestational age, suggesting that GSH deficiency is
present in the lungs of preterm infants and that the deficiency increases with the
degree of prematurity (Jain et al. 1995).
The role of ROS and RNS in the development of hypertension
It is clearly established that NO·  plays a critical role in several renal processes,
including regulation of renal plasma flow, glomerular filtration rate, renin and
angiotensin generation, and sodium excretion (Kone and Baylis 1997). All three
types of NOS are expressed in the kidney in a cell type-specific manner and are
subject to complex and distinct control mechanisms. The role of each NOS
isoform in renal processes is somewhat unclear, since most studies have been
done using non-specific NOS inhibitors. However, NOS I and NOS III appear to
be involved in the regulation of renal plasma flow and glomerular filtration rate,
and NOS II in tubular sodium transport (Kone and Baylis 1997, Gabbai and
Blantz 1999). Thus NO·  appears to be critical in normal sodium excretion and
renal hemodynamics, and impediment of its actions leads to disturbance in
kidney homeostasis that may promote hypertension.
Both human essential hypertension as well as many experimental animal
models of hypertension, such as the spontaneously hypertensive rat (SHR), are
associated with increased production of ROS and/or low levels of antioxidants.
Increased production of ROS, notably O2·- , leads to inactivation of NO· , thus
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preventing its vasodilatory action (Gryglewski et al. 1986). The evidence for
involvement of ROS in human hypertension is indirect: essential hypertension
has been shown  to be associated with increased plasma levels of lipid
peroxidation products (Russo et al. 1998), and clinical studies show that ascorbic
acid improves endothelium-dependent vasodilation and reduces blood pressure in
hypertensive patients (Taddei et al. 1998, Duffy et al. 1999). In SHR, increased
production of O2·-
 has been shown in mesenteric arterioles (Suzuki et al. 1995),
and a synthetic membrane-permeable SOD mimetic normalizes the blood
pressure (Schnackenberg et al. 1998). Also xanthine oxidase inhibitors attenuate
the rise in blood pressure in SHR, suggesting that xanthine oxidase may be a
source of ROS generation that is associated with an increasing arteriolar tone in
SHR (Nakazono et al. 1991) (Suzuki et al. 1998). It should be noted, however,
that xanthine oxidase inhibitors do not inhibit exclusively xanthine oxidase.
Another possible source of ROS in SHR is dysfunctional NOS III (Cosentino et
al. 1998).
While the kidney has been shown to be crucial in the development and
maintenance of hypertension, the possible involvement of renal ROS production
in hypertension has drawn relatively little attention. Angiotensin II increases O2·-
production in vascular smooth muscle cells and adventitial fibroblasts
(Griendling et al. 1994, Pagano et al. 1998), as well as in kidney mesangial cells
(Jaimes et al. 1998). Thus at least in angiotensin II-dependent hypertension, there
appears to be an increase in renal O2·-  production, which is likely to attenuate
NO· -mediated effects. In SHR, increased salt intake leads to an increase in blood
pressure and in renal xanthine oxidoreductase activity, but the increase is mainly
in the dehydrogenase form, which does not produce ROS (Laakso et al. 1998).
Studies on ROS in the kidney face technical problems similar to those in studies
on NO· , because the specific site and the source of ROS is important to know in
order to understand their role in renal processes.
Increased oxidative stress in SHR may be caused not only by enhanced
production but also by lowered antioxidant capacity. In this respect, it is of
interest that increased O2·- generation in the myocardium of SHR has been shown
to be associated with low activities of MnSOD and CuZnSOD, implying
decreased antioxidant protection (Ito et al. 1995). Little is known about GSH
synthesis or the enzymes of the GSH redox cycle in SHR in comparison to WKY,
and the reports are somewhat controversial. Myocardial GCS has been reported
to be higher in SHR that in WKY (Carlos et al. 1998). GPx activity has been
reported to be either higher (Cabell et al. 1997), similar (Yuan et al. 1996) or
variable depending on age (Batist et al. 1989), and hepatic GPx activitity lower
(Kitts et al. 1998) in SHR in comparison to WKY. However, no systematic
studies have been made to elucidate the activities of all the enzymes in GSH
redox cycle or GSH synthesis in these animals.
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The role of ROS and RNS in the secondary effects of hypertension
Hypertension injures blood vessels, thereby causing end-organ damage. While
many steps in the process are not completely understood, recent advances in the
understanding of the chain of events have made it possible to construct a tentative
model of hypertensive kidney damage (Luft et al. 1999). According to this model,
the primary signaling event is increased blood flow through small arteries, which
has been shown to increase connective tissue production and promote medial
hypertrophy, probably through proliferation of both endothelial and vascular
smooth muscle cells (Tulis et al. 1998). The endothelial layer acts as a signal
transduction interface for hemodynamic forces: both shear stress (the tangential
force due to blood flow) and cyclic strain (circumferential stress due to
transmural pressure) initiate numerous growth-promoting pathways, e.g. release
of growth factors (Chien et al. 1998). Furthermore, cyclic strain increases the
formation of ROS, presumably by activation of NAD(P)H oxidase (Howard et al.
1997). This leads to an upregulation of leukocyte chemoattractants, such as
monocyte chemotactic protein-1 (MCP-1) (Wung et al. 1997), as well as
adhesion molecules, such as intercellular adhesion molecule-1 (ICAM-1) (Cheng
et al. 1998). Infiltration of the permeabilized endothelium by leukocytes initiates
an inflammatory cascade leading to vascular and mesangial cell proliferation and
hypertrophy, increased coagulation and matrix production, and ultimately end-
stage renal failure.
While mechanical forces are crucial in initiating the events leading to vascular
remodeling and subsequent end-organ damage, other mediators are involved as
well. Rats transgenic for both human angiotensinogen and renin genes (dTGR),
develop severe cardiac and renal damage and die by 7 weeks of age, despite an
only modest increase in blood pressure (Luft et al. 1999). These effects are
reversed by angiotensin converting enzyme (ACE) inhibitors and angiotensin II
type 1 (AT-1) receptor inhibitors and, interestingly, by PDTC (Muller et al.
2000). The latter is an inhibitor of NF-kB (Schreck et al. 1992, Liu et al. 1999),
and has also been shown to be a non-specific scavenger of ROS as well as to
increase cellular GSH levels through induction of GCS (Wild and Mulcahy 1999,
Moellering et al. 1999b). These results indicate that angiotensin II contributes to
hypertensive vasculopathy. Indeed, angiotensin II affects growth-promoting
processes directly as well as indirectly through synthesis of growth factors such
as platelet-derived growth factor (PDGF) and transforming growth factor b
(TGFb) (Raij 1999), and these synthetic pathways appear to be redox-regulated
(Sundaresan et al. 1995, Du et al. 1999).
Nitric oxide appears to antagonize the effects of angiotensin II in the
vasculature in many ways. It is a powerful inhibitor of vascular smooth muscle
and mesangial cell growth as well as extracellular matrix production (Du et al.
1999, Raij 1999, Garg and Hassid 1989). These effects have been elegantly
shown in vivo in NOS III knockout mice subjected to hemodynamic injury (Rudic
et al. 1998). Nitric oxide inhibits activation of the redox sensitive transcription
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factor NF-kB in response to pro-inflammatory cytokines, which in turn prevents
transcription of chemokines and adhesion molecules and subsequent leukocyte
infiltration (Zeiher et al. 1995, De Caterina et al. 1995, Peng et al. 1995). Nitric
oxide has also been shown to downregulate ACE synthesis (Higashi et al. 1995),
AT-1 receptors in vascular tissue (Ichiki et al. 1998), and TGF-b1 expression
(Craven et al. 1997). Thus the antagonistic interaction of NO·  and angiotensin II,
and the balance between these two, appears to be important in the development
of end-organ damage.
In conclusion, it is reasonable to hypothesize that in hypertensive end-organ
damage the effects of angiotensin II override the effects of NO· . Increased
production of ROS upon stimulation by angiotensin II may initiate a pro-trophic
and pro-inflammatory cascade, which ultimately leads to end-organ damage.
While the role of glutathione in this process is yet to be established, many of
these pathways are potentially affected by intracellular thiol status.
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OBJECTIVES OF THE STUDY
The hypothesis underlying this series of studies is that glutathione plays an
important role in antioxidant defense, exemplified by two clinical situations,
preterm birth and hypertension. Therefore, studies were performed to assess the
ability of the premature neonate to synthesize glutathione, and to generate its
rate-limiting substrate, cysteine, through the transsulfuration pathway.
Furthermore, the role of glutathione in hypertension was studied in a genetic
animal model of hypertension, the spontaneously hypertensive rat.
The specific aims were:
1. To study the mRNA expression and activity of the rate-limiting enzyme of
GSH synthesis, g-glutamylcysteine synthetase, in human  fetal, neonatal and
adult lung, liver, and kidney.
2. To study the mRNA expression and activity of cystathionine g-lyase i  the
human fetal, neonatal, and adult liver, to assess the ability of its two mRNA
isoforms to code for active enzyme, and to elucidate whether alternative
splicing accounts for the two isoforms.
3. To study GSH metabolism in the spontaneously hypertensive rat and to
determine the role of NO·  in the regulation of GSH synthesis in this
experimental model.
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MATERIALS AND METHODS
Human samples
Fetal lung, liver, and kidney samples (15 to 19 gestational wk) (N=6) were
obtained from legal abortions. The samples between 26-42 gestational weeks
were obtained from neonatal autopsies performed within 12 h of death. The
causes of death were respiratory distress syndrome (RDS) (N=2), congenital
heart disease (N=1), respiratory failure and hydronephrosis (N=1), and meconium
aspiration (N=1). Adult lung tissue samples (N=3) were obtained from
macroscopically normal tissues of lung cancer patients undergoing lung surgery
and from donor lungs of single lung transplantations. Adult liver tissue (N=4)
was obtained from partial liver transplantations. Kidney tissue (N=5) was
obtained from renal biopsies or from cadaver donors.
The study protocol was approved by the Ethical Committees of The Hospital
for Children and Adolescents, and Department of Thoracic and Cardiovascular
Surgery, University of Helsinki, Helsinki, Finland.
Experimental animals
In the first set of experiments, 47 inbred nine-week-old male SHR rats (Harlan
Sprague Dawley Inc, IN, USA) weighing 240 - 250 g were divided into six
groups. The animals were kept three weeks on diets containing 0.2, 1.1 or 6.0 %
of NaCl (w/w of the diet) with or without Nw-nitro-L-arginine methyl ester (L-
NAME, 0.025 % in the diet, providing approximately 20 mg/kg body
weight/day). In the second experiment, 20 nine-week-old SHR, weighing 190 -
250 g, were divided into two groups, receiving 6.6 % NaCl in diet with or
without isosorbide-5-mononitrate (IS-5-MN, 0.1 % w/w of the diet, providing 60-
70 mg/kg body weight/day) for eight weeks. In the third experiment, fourteen
eight-week-old SHR rats (Harlan Sprague Dawley Inc, IN, USA) weighing 240 -
250 gm were divided into two groups. They were kept for 6 weeks on diets
containing either 0.3 % (low-salt) or 2.6% (high-salt) NaCl (w/w of the diet). The
control Wistar-Kyoto rats (n=8) were kept on a diet containing 0.3% NaCl.
The procedures and protocols for the animal studies were in accordance with
the institutional guidelines and were approved by the Animal Experimentation
Committee of the Intitute of Biomedicine, University of Helsinki, Finland.
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The systolic blood pressure and heart rate of the rats were measured with the
use of a tail-cuff analyzer (Apollo-2AB Blood Pressure Analyzer, Model 179-
2AB, IITC Life Science) as described (Vaskonen et al. 1997). The digital values
for systolic blood pressure and heart rate were evaluated automatically from the
analog data by a microprocessor. Before the measurements the rats were warmed
for 10 to 20 min at 28°C to make the pulsations of the tail artery detectable. The
average of three readings was used. To minimize the stress-induced fluctuations
in blood pressure, all measurements were taken by the same person in the same
quiet environment between 2 and 6 p.m.
Enzyme activity measurements
Frozen human samples were homogenized in 100 mM Tris-HCl buffer (pH 8.2)
containing 50 mM KCl, 20 mM MgCl2 and 2 mM EDTA. The homogenates were
centrifuged at 14,000 x g for 30 min at 4°C. The liver and lung homogenates
were filtered through P-10 gel filtration columns (Pharmacia) and kidney
homogenates through Micro Bio-Spin 6 Column (Bio-Rad, Hercules, CA). GCS
activity was measured as described (Nardi et al. 1990), with modifications.
Briefly, the assay mixture (final volume 100 µl) containing 10 mM ATP, 6 mM
DTT, 3 mM L-cysteine and 15 mM L-glutamic acid in 100 mM Tris-HCl buffer
was preincubated at 37°C for 15 min to ensure complete reduction of thiols. The
reaction was initiated by addition of the sample. The samples were incubated for
15-30 min at 37°C. After the incubation 50 µl of the mixture were added to 50 µl
of 30 mM monobromobimane (ThiolyteÒ, Calbiochem, La Jolla, CA) in 50 mM
N-ethylmorpholine (pH 8.4) and left to react at room temperature for 5 min. The
reaction was stopped by addition of 10 µl 100% TCA and the precipitated protein
was spun down at 14,000 g for 5 min. 5 µl of supernatant were injected into a
Waters Novapak C-18 HPLC column (4 µm, 3.9 x 150 mm) running an isocratic
mobile phase consisting of 4% acetonitrile, 0.25% acetic acid and 0.25%
perchloric acid, pH 3.7. The fluorescent product was detected using Shimadzu
RF-10AxL spectrofluorometer (Shimadzu Corporation, Kyoto, Japan) with
excitation and emission wavelengths of 394 nm and 480 nm, respectively. The
quantity of g-glutamylcysteine was measured by comparison with g-
glutamylcysteine (Bachem, Bubendorf, Switzerland) standards derivatized and
analyzed as above. Enzyme activity was normalized on the basis of protein
content, which was determined using Bio-Rad DC protein assay kit.
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For cystathionine g-lyase activity measurements, the cultured cells were
harvested and suspended in ice-cold 10 mM sodium phosphate buffer (pH 7.0)
containing 1 mM EDTA. After 3 freeze-thaw cycles the non-soluble debris was
spun down and the supernatant used for activity measurement. Frozen liver
samples were homogenized in 30 mM sodium phosphate buffer (pH 7.0),
centrifuged at 14,000 x g for 30 min at 4°C, nd filtered through P-10 gel
filtration columns (Amersham Pharmacia Biotech) to remove endogenous amino
acids. Enzyme activity was measured as described (Heinonen 1973). The
specificity of the assay was confirmed using propargylglycine, an inhibitor of
CGL.
Spectrophotometric assays were used to measure GPx, GR and G6PDH
activities. GPx was measured by following the oxidation of NADPH in the
presence of t-BOOH, GSH and GR (Beutler 1975b), and GR and by following
NADPH oxidation in the presence of GSSG (Beutler 1975a) at 340 nm. G6PDH
was measured by following the reduction of NADP in the presence of glucose-6-
phosphate (Löhr and Waller 1974).
mRNA detection
Total RNA was extracted from 293T cells using RNeasy mini kit (Qiagen). For
the extraction of total RNA from tissues, the guanidinium thiocyanate/cesium
chloride method was used (Chirgwin et al. 1979).
For the detection of CGL by Northern blotting, RNA was fractionated on
agarose-formaldehyde gels at 10 µg/lane. Following capillary transfer onto nylon
filters (Hybond-N, Amersham Pharmacia Biotech), the blots were hybridized
using standard methods (Sambrook et al. 1989) with [32P] labeled (DuPont)
complementary RNA probe corresponding to nucleotides 874-1106 of the
published sequence (Lu et al. 1992). Following hybridization and washes, the
filters were exposed to Kodak BioMax MR autoradiography films (Eastman
Kodak Co.) The filters were stripped and reprobed with [32P] labeled
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) RNA probe transcribed
from p-TRI-GAPDH-plasmid (Ambion).
For quantification of RNA from fetal, neonatal and adult tissues, the
ribonuclease protection assay (RPA II, Ambion Inc) was used. For the detection
of GCS subunits, 32P-radiolabeled antisense RNA probes were transcribed from
the PstI-NcoI fragment of GCSh (nucleotides 1375-1628) (Gipp et al. 1992), and
the HindII fragment of GCSl cDNA (nucleotides 583-888) (Mulcahy and Gipp
1995), and hybridized with 10 µg (liver and kidney) or 20 µg (lung) total RNA at
42°C overnight. In order to detect GCL-L and CGL-S, templates for radiolabeled
RNA probes were generated by amplifying 301-bp and 169-bp fragments of
CGL-L and CGL-S using the forward primer 5’-GCAAGTGGCATC-
TGAATTTG-3’ and reverse primer 5’-CCCATTACAACATCACTGTGG-3’
flanking the deletion site. The resulting fragments were cloned into the pCR 2.1
cloning vector (Invitrogen) and digested with SpeI. Using T7 RNA polymerase
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and [32P]UTP, these vectors yield 397- and 265-bp radiolabeled run-off
transcripts and 299- and 167-bp protected fragments for CGL-L and CGL-S,
respectively. To normalize for RNA content, the samples were hybridized with
RNA probes transcribed from human b-actin cDNA (pTRI-Actin-Human,
Ambion Inc.). Following RNase A+T1 digestion, the protected fragments were
separated on 5% polyacrylamide/8 M urea gels and exposed to Kodak BioMax
MR autoradiography film (Eastman Kodak Co, Rochester, NY).
For RT-PCR, liver RNA samples were reverse transcribed using random hexamer
primers (Promega) and amplified using the same primers that were used for
creating probes for the ribonuclease protection assay.
In vitro expression of CGL
Cell culture and transfections
Human embryonic adenovirus-transformed kidney cells (293T cells) were
maintained in Dulbecco’s modified Eagle’s medium with 862 mg/l Glutamax IÔ
(Gibco BRL) supplemented with 10% (v/v) heat-inactivated fetal calf serum, 100
units/ml penicillin and 100 µg/ml streptomycin. Cells were seeded at a density of
4 x 106/10-cm plate 20 h before transfection. Cultures were grown at 37°C in a
humidified atmosphere with 5% CO2. Transient transfections were performed
using FuGENEÔ 6 Transfection Reagent (Roche Molecular Biochemicals)
according to the manufacturer’s protocol. Cells were transfected with 6 µg of
pcDNA-CGL-S, pcDNA-CGL-L or pcDNA3. Transfection efficiency was
monitored by cotransfection of 1.5 µg of pCMVb (Clontech) b-galactosidase
expression vector and measuring b-galactosidase activity as described (Rosenthal
1987). Cells were harvested 48h after transfection.
Plasmids carrying cystathionine g-lyase isoforms
Human cystathionine g-lyase cDNA (HCL-1, GenBank acc. #52028) was
obtained from American Type Culture Collection (ATCC, Rockville, MD, USA,
cat. no. 79761). This cDNA clone represents the shorter CGL isoform. However,
the original clone obtained from ATCC lacked the 3’ end (nucleotides 1106-
1194) of the reported sequence of the short form of CGL (Lu et al. 1992). The
missing nucleotides of the coding sequence, a Kozak consensus translation
initiation sequence and restriction sites were added to the sequence by PCR. The
sequences of the primers used were as follows: forward 5’-
CTCTGGTACCGCGACCATGCAGGAAAAAGACGCCTCCTC and reverse 5’-
CGTCGGTACCCTAGCTGTGAATTCTTCCACTTGGAGGGTGTGC (sequences
corresponding to the human CGL are italicized and KpnI restriction sites are
underlined). pcDNA-CGL-S was created by cloning the resulting DNA fragment
into the KpnI site of the mammalian expression vector pcDNA3 (Invitrogen).
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In order to clone the longer isoform CGL-L, 1 µg of total human liver RNA
was reverse transcribed using random hexamer primers (Promega) and PCR
amplified as above. The CGL-S and CGL-L clones were sequenced using ABI
prism automated sequencer (Perkin-Elmer).
PCR of genomic DNA
Our assumption was that the two CGL forms are splice variants and the 132 bp
fragment missing from CGL-S is flanked by two introns. DynaZyme EXT DNA
Polymerase (Finnzymes) was used to obtain the PCR fragments. For the
amplification of the 5’ intron, 100 ng of human genomic DNA were amplified
using forward primer 5’-GCAAGTGGCATCTGAATTTG-3’ and reverse primer
5’-ACAATATGTGCACAGCCTTC-3’. The resulting ca. 2.3 kb fragment was
cloned into pCR-XL-TOPO vector (Invitrogen) and sequenced from both ends of
the insert. The 3’ intron was amplified using forward primer 5’-
AACCCCACCCAGAAGGTGATTG-3’ and reverse primer 5’-GCAGAATAC-
ATAGAAATATCAGCTCC-3’. PCR amplification resulted in ca. 5 kb DNA
fragment, which was then cloned and sequenced as above.
Statistical Analysis
For comparing the expression of GCS in fetal, neonatal and adult tissues, the
Mann-Whitney U-test was used with a level of P£0.05 chosen to indicate
significant differences. The Spearman rank correlation test was used to assess the
correlation between enzyme activity and mRNA levels.
The CGL activity in cells transfected with CGL-S, CGL-L or empty plasmid
were compared with Student’s t-test. Data were expressed as mean ± S.E.M.
Linear regression was used to assess the correlation between the mRNA
expression of CGL-S and CGL-L during development.
In studies on experimental animals, comparisons between treated and non-
treated animals were carried out using Student’s t-test. The activities were
expressed as mean ± S.D.  The relationship between GCS activity and blood
pressure was assessed using Pearson’s linear correlation coefficient.
All statistical analyses were performed with the SPSS 8.0 program (SPSS
Inc.).
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RESULTS
The expression of GCS
In the liver, both GCS mRNA species were detectable using Northern blotting,
whereas in other tissues only the ribonuclease protection assay was sensitive
enough to detect GCSl and GCSh. Neither mRNA expression of GCSl and GCSh
nor the GCS activity in the fetal and neonatal liver differed significantly from
adult samples. The mean activity of GCS was three to four times higher in the
liver than in other tissues studied (4.4 nmol/min/mg protein).
In the lung, the mRNA expression of GCSh was at the same level in fetal,
neonatal and adult groups, whereas GCSl expression was higher in the neonates
than in the fetuses and the adults (p=0.03). The mRNA expression of GCSl was
highest in two neonatal patients (gestational age 26 weeks) who died of RDS.
Also the highest specific activity (1.9 nmol/min/mg protein) in the lung was
measured from one of the RDS patients. There was no statistically significant
difference in the GCS activity in fetal, neonatal and adult groups.
The mRNA expression of GCSh in the kidney was at the same level in all
groups. The GCSl expression was significantly lower in the fetuses than in the
neonates and the adults (p=0.02), but GCSl mRNA expression did not correlate
with enzyme activity (r=-0.03). The GCS activity in the adults was statistically
significantly higher than in the fetuses and the neonates (p=0.03), but this may be
accounted for by the variation in the small number of samples.
Developmental and in vitro expression of CGL
The expression of CGL during development
CGL activity was only detected in adult liver tissue (68±9 nmol cysteine/h/mg
protein), whereas activities in fetal, preterm and term neonatal liver samples were
undetectable. In contrast, mRNA expression was detected from the 19th
gestational week onwards, and the mRNA levels were comparable to those of
adult liver samples. The expression of the two mRNA forms varied in parallel
(r=0.94, p<0.001). Since in the ribonuclease protection assay the length and the
specific activity of the probe affect the intensity of the signal, exact
quantification of mRNA is not possible by this method. However, the results of
the RT-PCR suggest that the longer form is more abundant in the liver throughout
development.
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Splice variation on cystathionine g-lyase
Amplification of the 5’ intron from genomic DNA resulted in ca. 2.3 kb PCR
fragment, in which the first 93 nt from the 5’ end as well as 71 nt from the 3’ end
were similar to the reported cDNA sequence (Lu et al. 1992). A BLAST
sequence similarity search of the GenBank database did not show similarity to
any other known nucleotide sequences. At the putative exon-intron boundaries,
consensus U2-type GT-AG 5’ donor and acceptor sequences (Sharp and Burge
1997) were found (Figure 7).
Figure 7. (A) Exon-intron structure of the human cystathionine g-lyase g ne at
the site of splice variation. Exons are indicated as empty boxes and introns as
thin lines. Primer positions are indicated by arrows numbered as follows: #1 and
#2: The forward and reverse primers for amplification of intron a, #3 and #4:
The forward and reverse primers for amplification of intron b. (B) Exon-intron
junctions of the human cystathionine g-lyas gene. Sequences flanking exon-
intron junctions are aligned with consensus splicing sequences. K indicates a or
c, r indicates either purine (a or g), y indicates either pyrimidine (c or t), and n
indicates any base. Exon sequences are in uppercase letters and intron
sequences in lowercase letters. The intron positions in cDNA are shown as
subscript numbers.
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Of the 5 kb DNA fragment resulting from the amplification of the 3’ intron,
108 nucleotides at the 5’ end and 41 nt from the 3’ end were similar to the
reported cDNA sequence and to no other sequence found in a BLAST search.
The putative exon-intron junctions were consensus sequences (Figure 7) (Sharp
and Burge 1997). The fragment  missing in CGL-S appears to be coded by a
single exon as the two genomic PCR fragments were overlapping.
Enzyme activity in 293T cells transfected with different cystathionine g-lyase
isoforms
There was a 1.5-fold increase in CGL activity 293T cells transfected with
pcDNA-CGL-L compared to cells transfected with an empty pcDNA3 vector
(Figure 8). Transfection with pcDNA-CGL-S did not cause any increase in
activity. Although the change from basal activity was small, it was consistent and
reproducible. Efficient transcription of both isoforms in transfected cells was
verified by Northern blotting. The CGL mRNA expression of cells transfected
with pcDNA-CGL-L and pcDNA-CGL-S was 7-fold and 11-fold, respectively, in
comparison with basal CGL mRNA expression of mock-transfected cells. The b-
galactosidase activities of the cells co-transfected with b-galactosidase
expression vector were of the same order.
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Figure 8.   Total cystathionine g-lyase
activity in 293T cells transfected with
the two CGL isoforms.
Control cells were transfected with 6 mg
of an empty pcDNA3 vector; CGL-L,
cells transfected with 6 mg of pcDNA-
GCL-L; CGL-S, cells transfected with 6
mg of pcDNA-GCL-S, N=11 in each
group. Samples are from four
independent experiments. Mean ±
S.E.M. is given. Significance compared
with control cells: *** P<0.001.
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Glutathione metabolism in the spontaneously hypertensive rat
The effect of NOS inhibition on enzymes involved in GSH metabolism in the
kidney
L-NAME treatment led to a significant down-regulation of GCS activity (Figure
9). The reduction was largest in the high-sodium group. The GCS activity
correlated negatively with the systolic blood pressure at the end of the follow-up
period (r = -0.60, p < 0.001) and with the change in systolic blood pressure
during the study (r = -0.52, p < 0.001).
L-NAME treatment had no effect on kidney GPx activity in any salt group
(Table 4). Glutathione reductase activities were lower in rats treated with L-
NAME, and this difference was statistically significant in the group receiving
1.1% NaCl in their diet.
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Figure 9. g-glutamylcysteine
synthetase activity in kidneys of
spontaneously hypertensive rats
treated with (solid bars) or without
(open bars) Nw-nitro-L-arginine
methyl ester and receiving a diet of
variable NaCl content (LS=NaCl
0.2%, MS=NaCl 1.1%, HS=NaCl
6.0%), n indicates the number of
animals in each group. Mean ± SD is
given. * p < 0.05, *** p<0.001.
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The effect of NO·  donor on enzymes involved in GSH metabolism in the kidney
Isosorbide-5- mononitrate treatment did not have an effect on the renal GCS
activity (190 ±35 and 191 ±36 nmol/min/mg protein with and without IS-5-MN,
respectively) in the SHR. Also GPx and GR activities were unaffected by this
treatment (Table 4).
Enzymes involved in GSH metabolism in SHR in comparison to WKY
In the kidney, the increases in GR and GCS activities, seen in both low salt and
high salt SHR groups compared to WKY, did not reach statistical significance
(p=0.07 and p=0.11, respectively). GPx and G6PDH activities were similar in all
groups.
In the left ventricle of the heart, GPx, GR, and G6PDH activities did not differ
between the groups (Table 5). GCS activity was below the detection limit of our
assay. In the liver, the activities of GCS, GR and G6PDH were similar in all
groups, whereas GPx was significantly lower in SHR.
Table 4. Glutathione peroxidase (GPx), glutathione reductase (GR) and glucose-
6-phosphate dehydrogenase (G6PDH) activities in spontaneously hypertensive
rats treated with L-NAME or isosorbide 5-mononitrate (IS-5-MN). *: p<0.01
with respect to control salt group.
                   GPx  GR     G6PDH
0.2% NaCl
0.2% NaCl + L-NAME
1.1% NaCl
1.1% NaCl + L-NAME
6.0% NaCl
6.0% NaCl + L-NAME
6.6% NaCl
6.6% NaCl + IS-5-MN
46.5±6.0
36.0±8.1
45.7±6.4
42.5±2.5
43.8±5.0
45.6±12.1
77.3±11.3
80.8±12.7
88.9±13.6
78.1±8.6
89.6±6.1
73.3±7.4*
86.8±8.0
75.9±13.8
69.6±6.8
71.5±8.0
15.8±0.8
17.0±1.5
15.3±1.0
17.5±1.4*
15.3±1.0
17.8±2.0*
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Table 5. Enzymatic activities of g-glutamylcysteine synthetase (GCS),
glutathione peroxidase (GPx), glutathione reductase (GR), and glucose-6-
phosphate dehydrogenase (G6PDH) in heart and liver homogenates.
WKY: Wistar-Kyoto controls (n=8), SHR LS: spontaneously hypertensive
rats on 0.3% NaCL diet (n=7), SHR HS: SHR on 2.6% NaCl diet (n=7).
All data are mU/mg protein, and mean±S.D. are given. **: p<0.01.
Group Tissue GCS GPx GR G6PDH
WKY Heart n.d. 33.1±9.2  6.3±1.9 3.3±1.0
Liver 9.1±1.7 119.3±17.9 47.3±12.3 9.9±2.5
SHR LS Heart n.d. 34.1±6.1  6.1±2.3 3.3±1.9
Liver 8.7±1.1 89.1±36.1**  45.3±3.8
8.5±1.5
SHR HS Heart n.d. 33.7±2.3  6.5±1.5 2.5±1.1
Liver 8.0±1.0 100.2±14.4** 45.4±3.0 8.9±1.7
Blood pressure
During the follow-up period of 6 weeks, the blood pressure in SHR increased
44±10 mmHg and 59±  mmHg on low- and high-salt diets, respectively, whereas
in control rats the blood pressure did not change. The increase in blood pressure
in the high-salt group was significantly higher (p<0.01) than in the low-salt
group.
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DISCUSSION
The expression of enzymes involved in GSH synthesis during human
development
The expression of g-glutamylcysteine synthetase
Given the multitude of GSH-related cellular functions and especially the
important role of GSH in cell proliferation (Cotgreave and Gerdes 1998), it is
likely that the enzymes needed for GSH synthesis are expressed from early stages
of embryonic development. Indeed, GCS has been shown to be expressed at the
early head-fold stage (day 9.5) in rats (Trocino et al. 1995). Interestingly, high
glucose concentration causes a decrease in its expression and a subsequent
decrease in GSH concentration, which is associated with increased incidence of
embryonic malformations and growth retardation. These effects are almost
completely reversed by a GSH ester. Although the cDNAs for both subunits of
mouse GCS have been cloned (Reid et al. 1997), GCS or GSH synthetase knock-
outs have not been described. It is highly likely that such knock-outs are
embryonically lethal. Mice lacking MTF-1, who have diminished hepatic
expression of GCS, die in utero with hepatic failure (Gunes et al. 1998). In
human liver (Rollins et al. 1981) and erythrocytes (Lestas and Rodeck 1984),
GCS activities are at the same level in fetuses as adults, supporting the notion
that GSH synthetic capacity is mature at early developmental stages. However, as
GCS may be differentially regulated in various tissues, it is of importance to
investigate the expression of GCS in those tissues that are critically exposed to
ROS, such as the lung. The low concentration of GSH in the epithelial lining
fluid of preterm newborn infants (Grigg et al. 1993) may reflect the immaturity of
the lung to synthesize GSH efficiently.
Our results show that GCS mRNA expression and activity do not differ
appreciably between fetal, neonatal and adult groups in the tissues studied. The
highest GCS activity was measured in the liver, and the activities in the lung and
in the kidney were lower but similar. As GCS is expressed and active in these
tissues already in the second trimester, GCS appears to be fully operative also in
preterm infants. It is of interest that GCS activity is two orders of magnitude
higher in rat than in human kidney (Neuschwander-Tetri et al. 1997). This may
explain why GCS activity is drastically increased postnatally in rats and mice
(Tsui and Yeung 1979, Harman et al. 1990), but not in humans. Furthermore, g-
GT activity is also much higher in rat than in human kidney tissue (Hinchman
and Ballatori 1990). These differences in tissue-specific expression of GCS and
g-GT between humans and rodents reflect differences in inter-organ GSH
metabolism, as the kidney rather than the liver is the principal site of GSH
salvage in rats.
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The in vitro and developmental expression of cystathionine g-lyase
Cystathionine g-lyase activity (Sturman et al. 1970) has been shown to be absent
from human fetal liver. As two mRNA forms of CGL have been found in human
liver, it was postulated that changes in the relative expression of the two isoforms
causes the postnatal increase in activity (Lu et al. 1992). It was proposed that the
expression of the longer isoform would dominate during the fetal period and the
protein coded by it would be inactive. Later on, the expression of the shorter
mRNA form would increase causing the postnatal increase in activity. However,
the shorter form of CGL lacks 44 amino acid residues, including the catalytically
indispensable residues Asp187 and Asn188, which are conserved in all members
of the g-family of PLP dependent enzymes (Steegborn et al. 1999). This suggests
that the shorter form would be inactive.
In our study, only those cells transfected with the cDNA corresponding to the
longer form of CGL had increased enzymatic activity, although both mRNAs
were efficiently transcribed. Transfection with the shorter form neither increased
nor decreased the basal CGL activity. The deletion of the shorter form is at the
catalytic area, while those residues interacting with the other subunits of the CGL
tetramer remain intact. Therefore, it is likely that the shorter form would interact
with the longer form, but does not inhibit its activity. However, the missing
fragment in the shorter form of GCL would necessitate major movements of the
secondary structure elements, which may result in a considerable alteration of the
tertiary structure. Futhermore, as we have no means to detect CGL protein, it is
possible that CGL-S protein is degraded rapidly, as has been shown for rat
cystathionine b-synthase (Roper and Kraus 1992). Taken together, our findings
do not support the postulated regulatory function of GCL-S.
In the present study, CGL activity was only detected in adult liver tissue,
whereas activities in fetal, preterm and term liver tissues were undetectable. This
is in accordance with an earlier report (Sturman et al. 1970). In contrast, strong
mRNA expression was detected from the 19th gestational week onwards. That
the mRNA expression of both subunits varies in parallel and the longer form is
predominant throughout development further reinforces the notion that the
postnatal increase in the CGL activity is not regulated by the change in the
relative expression of the two isoforms. Although the discrepancy between CGL
mRNA expression and enzyme activity could be accounted for by an inhibitor
present in the crude extracts of fetal liver, or by CGL protein that is catalytically
inactive, earlier studies do not support these views (Sturman et al. 1970, Gaull et
al. 1972, Pascal et al. 1972). Rather, a likely explanation is post-transcriptional
regulation of CGL gene expression, as has been shown for a number of enzymes
during the development of the liver (Das et al. 1996, de Groot et al. 1987, de
Groot et al. 1986, Hryb and Feigelson 1983).
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Therapeutic possibilities of supplementation of GSH or its precursors
Theoretically, increasing intracellular GSH would be a rational approach to
antioxidant therapy. As GSH itself is not efficiently transported into most cells,
supplementation of GSH precursors, preferably the limiting substrate cysteine,
would be more feasible. This is especially relevant to preterm neonates, who
cannot synthesize cysteine themselves due to absent g-cystathionine activity.
However, cysteine is not very stable in intravenous solutions, and it has a narrow
therapeutic window (Anderson and Meister 1987). Therefore, cysteine precursors
could be used to augment cellular GSH.
N-acetylcysteine (NAC) has a thiol group that can directly scavenge certain
oxidants. However, its major antioxidant effect is thought to be based on
deacylation to cysteine, which is then used for GSH synthesis (Moldeus and
Cotgreave 1994). NAC given intravenously is the established treatment for
acetaminophen (paracetamol) poisoning (Vale and Proudfoot 1995). It is also
used orally as a mucolytic agent (Grassi and Morandini 1976). There are a
number of animal studies showing beneficial effects of NAC in various animal
models of lung injury (Bernard et al. 1984, Leff et al. 1993, Sprong et al. 1998),
but also opposite results have been reported (van Klaveren et al. 1997). In
preterm guinea pigs, NAC ameliorates hyperoxic lung  injury (Langley and Kelly
1993), but in mouse lung it does not protect against the detrimental effects of
hyperoxia on pulmonary growth (Wilborn et al. 1996). In clinical studies,
intravenous NAC have been shown to improve lung function in acute respiratory
distress syndrome (ARDS) in some studies (Suter et al. 1994, Bernard et al. 1997,
Jepsen et al. 1992), but others failed to see any effect (Domenighetti et al. 1997,
Laurent et al. 1996). Given orally, NAC did not produce a sustained increase in
GSH levels sufficient to increase the antioxidant capacity of the lungs
(Bridgeman et al. 1994). In conclusion, both experimental studies with adult and
preterm animals and clinical studies with adult patients have shown somewhat
contradictory results, and no clear consensus exists, as to whether or not NAC is
beneficial in the treatment of experimental or clinical lung injury.
With respect to preterm neonates, antioxidant therapy by NAC is an especially
attractive option because of their relative cysteine deficiency. However, there are
several potential problems. Nothing is known about the ability of preterm
neonates to deacetylate NAC, and it is possible that their ability to deacetylate
NAC and to utilize liberated cysteine for GSH synthesis is limited. Nevertheless,
NAC may increase intracellular GSH through reduction of extracellular cystine to
cysteine, thus augmenting cellular uptake of this amino acid. Moreover, thiols are
strong reductants able to reduce transition metal ions, which participate in Fenton
chemistry. They can also react to form reactive and potentially toxic thiyl radicals
(Munday 1989). In addition, optimal function of a number of molecules such as
cell membrane receptors and proteins involved in signal transduction may require
a balance between oxidized and reduced thiols. Interference with the homeostasis
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of these redox-sensitive pathways by excess amounts of  reductants may alter the
normal cell signaling that occurs upon oxidative stress (Cross et al. 1994).
Thiazolidines are potentially useful compounds for cysteine delivery. L-2-
oxothiazolidine-4-carboxylate (OTC) is readily taken up by cells and metabolized
by cellular 5-oxoprolinase to cysteine (Meister 1991). The efficacy of orally
given OTC against pulmonary oxygen toxicity has been shown in protein-energy
malnourished rats (Taylor et al. 1992). It has also been shown to improve the
clinical outcome of ARDS patients (Bernard et al. 1997). OTC is not a thiol
itself, so theoretically it does not have the extracellular adverse effects attributed
to the thiol group that NAC might have. The clinical use of OTC is limited
because it is not a registered drug. Futhermore, as the ontogeny of 5-oxoprolinase
has not been studied, it is remains to be established whether or not preterm
infants are able to metabolize it to cysteine.
Limitations of the study
All studies using human samples are fraught with technical and methodological
difficulties. In our study, there was large variation in enzyme activities and
mRNA levels between different individuals. This may in part be due to the fact
that the period between the time of death and autopsy was variable, although we
did not detect any correlation between the length of this time and enzymatic
activity or mRNA expression. All infants were treated in intensive care units for
up to five days before death, and all but one received oxygen therapy. Since both
GCS mRNA expression and activity have been shown to be induced upon
oxidative stress in lung epithelial cells (Shi et al. 1994, Tian et al. 1997), the
upregulation of GCSl in the lungs of 26 wk infants may well be caused by oxygen
therapy. Thus, all the changes observed in mRNA levels do not necessarily
reflect alterations of gene expression during development, but may be caused by
disease processes or therapeutic interventions.
Glutathione metabolism in experimental hypertension
The interplay of NO· and GSH in vascular function
There is ample evidence of a close interaction between NO·  and GSH
metabolism. In vitro, NO·  increases intracellular GSH concentration by inducing
GCS, as well as increasing cellular cystine uptake (Moellering et al. 1998,
Moellering et al. 1999a, Li et al. 1999). Conversely, GSH is needed for proper
function of NO synthases. In purified preparations of iNOS and nNOS,
glutathione is needed for full enzyme activity (Stuehr et al. 1990, Hofmann and
Schmidt 1995). Furthermore, NO·  synthesis is impaired in endothelial cells
depleted of GSH (Ghigo et al. 1993), but increased in endothelial cells treated
with NAC (Ramasamy et al. 1999). Thus NO·  and GSH synthesis appear to be
regulated in a reciprocal manner.
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In the vasculature, NO·  has a wide range of physiological functions, including
inhibition of leukocyte adherence, chemotaxis, and vascular smooth muscle cell
proliferation (Lane and Gross 1999). Intracellular thiol status appears to play a
role in all of these effects. This is relevant to the end-organ damage due to
hypertension, in which vascular smooth muscle cell proliferation and monocyte
infiltration occur. Thiol antioxidants appear to have similar anti-inflammatory
and antiproliferative effects to NO·  (Henkel et al. 1993, Wung et al. 1997, Du et
al. 1999). In this respect, it is of interest that marked increases in monocyte
infiltration into coronary vessels as well as in NF-kB activation and MCP-1
expression caused by chronic NOS inhibition in rats are effectively reversed by
intraperitoneal administration of NAC (Usui et al. 2000).
In our study, chronic inhibition of NOS by L-NAME led to a down-regulation
of GCS by 50% in the high salt group. Relatively little is known about the
correlation of the level of GCS down-regulation and glutathione content in vivo.
In a study by Drew t al. (Drew and Miners 1984), the effect of GCS inhibition
by BSO on kidney GCS activity and GSH levels was studied in mice. From
buthionine sulfoximine dose-response curves it could be estimated that down-
regulation of GCS by 50% resulted in a reduction of GSH by 50%. Although the
kidneys of adult mice appear to be unaffected by this degree of GSH deficiency
for three weeks (Meister 1991), it is likely that  in the case of secondary kidney
damage due to hypertension, in which ROS appear to be a significant contributor,
GSH depletion of this magnitude increases the damage.
It has to be emphasized that while GSH is the major intracellular thiol, many
complementary molecules and systems exist in the cell which may compensate
for the loss of GSH. Ascorbic acid, which is present in millimolar quantities,  can
replace GSH (Meister 1994). Catalase may substitute for the loss of GSH in the
disposal of hydrogen peroxide. With respect to thiol redox-signaling, other
redox-active molecules, such as thioredoxin, may compensate for GSH (Arrigo
1999). While the pharmacological effects of GSH augmenting drugs are not
easily discerned, it would be interesting to see whether other drugs such as GSH
ester or OTC could provide protection against the detrimental effects of chronic
NOS-inhibition that is seen in the kidney of SHR, in the similar manner to NAC
(Vaskonen et al. 1997, Usui et al. 2000).
There are a number obvious limitations in our study. Firstly, we did not
measure kidney GSH levels. Thus, decrease in GCS regulation could possibly be
due to down-regulation by high GSH levels. However, this seems unlikely, since
inhibition of NO·  synthesis by L-NAME is associated with increased production
of ROS both in vitro and in vivo (Niu et al. 1994, Usui et al. 1999, Usui et al.
2000). Secondly, nitrosoglutathione and other nitrosothiols were not measured,
and thus their role in NO·  storage and transport is not known. Thirdly, the kidney
has all three forms of NOS, and their specific functions and localizations are not
fully elucidated. Therefore, inhibition by a non-specific NOS inhibitor and
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measuring activity from total kidney homogenates does not provide information
about the role of different NOS isoforms in the regulation of GSH synthesis, nor
do we gain knowledge about the effect of NOS inhibition on GSH synthesis in
the various cells in the kidney. Furthermore, given the complex roles of NO·  in
the regulation of renal homeostasis such as sodium excretion, much of which is
yet to be characterized in detail, it is not easy to envision what impact the
inhibition of GSH synthesis would have on these mechanisms leading to renal
hypertension.
The role of GSH in hypertension
There are relatively few reports on glutathione metabolism in human or
experimental hypertension. When SHR rats have been compared to WKY, GPx
activity has been reported to be either higher (Cabell et al. 1997), similar (Yuan
et al. 1996) or variable depending on age (Batist et al. 1989), and hepatic GPx
activity lower (Kitts et al. 1998) in SHR in comparison to WKY. The
discrepancy may be at least partly be accounted for by differences between the
ages of the rats in different studies, as it has been shown that GPx activity in
myocardium decreases with advancing age (Batist et al. 1989).
Our results show that kidney GCS and GR activities tend to be higher in SHR
than WKY, which implies an enhanced capacity to produce reduced GSH. It is of
interest that even a small, 1.2-1.5 fold increase in GCS activity causes a 2-4 fold
increase in intracellular GSH levels (Shi et al. 1994, Mulcahy et al. 1997).
Considering the millimolar concentration range of  intracellular GSH, GCS
induction of this magnitude provides efficient protection against increased
oxidative stress.
GR regulation under oxidative stress is not very well characterized. While it is
known that GR is not increased upon exposure to hyperoxia in the lung
(Pietarinen-Runtti et al. 1998), nor is it affected by cytokines known to cause
increased oxygen radical formation (Kinnula et al. 1995), there may be tissue-
specific differences in the regulation of GR. In the kidney, an increase in GR
activity may provide an additional mechanism to maintain reduced GSH levels.
In the liver, GPx was lower in SHR than in WKY, which is in accordance with
earlier studies (Cabell et al. 1997, Kitts et al. 1998). SHR liver has been shown to
be more susceptible to GSH depletion by hydrogen peroxide (Kitts et al. 1998).
However, decrease in liver GSH does not necessarily lead to increased oxidative
damage (Kitts et al. 1998). Furthermore, as renal and cardiac damage are
hallmarks of secondary damage caused by hypertension, and the liver is not
affected, it is likely that the small decrease seen in our study in the liver GPx
activity is of minor importance.
49
CONCLUSIONS
The main conclusions of this thesis are as follows:
1) In terms of activity and and mRNA levels, the expression of the rate-limiting
enzyme of glutathione synthesis, g-glutamylcysteine synthetase, is higher in
the liver than in the lung and kidney, but does not  vary appreciably between
fetal, neonatal and adult samples. This indicates that glutathione synthetic
capacity of the preterm neonate is not limited by the lack of this enzyme.
2) The mRNA expression of both the longer and shorter cystathionine g-ly se
isoform is abundant from the 19th gestational weeks onwards, whereas the
enzyme activity is only present in adult liver. There is a close correlation
between the mRNA expression of both isoforms during development. Only the
longer isoform is enzymatically active when expressed in eukaryotic cells.
These results suggest that cystathionine g-lyase is post-transcriptionally
regulated during development, and argue against the hypothesis that the
subunit composition of cystathionine g-lyase tetramer would regulate its
activity during development.
3) Systemic inhibition of nitric oxide synthesis by L-NAME in spontaneously
hypertensive rats down-regulates renal g-glutamylcysteine synthetase activity,
which is likely to aggravate secondary kidney damage in hypertension.
4) GSH recycling and synthesis appears not to be weaker in SHR in comparison
to WKY. Rather, SHR tend to have higher renal GCS and GR activities
implying better ability to increase reduced GSH. This effect may be an
adaptive response to an increased oxidative stress.
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